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Abstract 
Background: Secoisolariciresinol diglycoside (SDG) is a polyphenolic plant lignan found in 
flax and sesame seeds as well as legumes, whole grains, fruits and vegetables. It is metabolized 
by the gut bacteria into two major enterolignans: enterolactone (ENL) and enterodiol (END). 
These enterolignans have been associated with reduced breast cancer risk and progression in 
population studies as well as decreased tumor growth in preclinical models of breast cancer.   
 
Methods: The impact of SDG supplementation on tumor growth in a mouse model of basal-like 
breast cancer was examined. C57BL/6 mice were fed a control diet (10% kcal from fat) or 
control diet with SDG supplementation (100 mg/kg food) for eight weeks, then both groups were 
orthotopically injected with E0771 mammary tumor cells. Tumor and distal mammary fat pad 
(DMFP) were analyzed by qPCR to determine relative mRNA levels of ERa and ERb. An 
inflammatory signaling qPCR array (Qiagen) was performed on DMFP, and a NF-kB target gene 
qPCR array (Qiagen) was performed on tumors. Tumors were stained by immunohistochemistry 
(IHC) for Ki67 to measure proliferation levels, phospho-p65 and p-STAT3 to determine 
inflammatory signaling pathway activation, as well as cleaved caspase 3 to determine levels of 
apoptosis. MFP were also stained for F4/80 to quantify macrophage infiltration. Serum level of 
cytokines were measured via luminex assay (Bio-Rad). Mouse E0771 tumor cells were treated 
with ENL and analyzed by qPCR to determine ERa and ERb expression. Mouse E0771 tumor 
cells were also treated with ENL, +/- lipopolysaccharide (LPS), and NF-kB activity determined 
via DNA-binding ELISA.  
 
Results: SDG supplementation significantly decreased tumor volume (p<0.05). SDG did not 
affect body weight or body fat percentage. ERb but not ERa expression in both tumor and 
DMFP were significant increased with SDG supplementation. ENL treatment of E0771 cells in 
vitro also increased ERb expression. SDG significantly decreased expression of F4/80, CRP, and 
other pro-inflammatory markers in the mammary tissue. IHC staining revealed no difference in 
tumor proliferation or apoptosis; however, SDG supplementation did reduce inflammatory 
signaling in the tumors, indicated by a significant decrease in phospho-p65 staining, as well as 
43 NF-kB target genes. However, serum cytokine levels were not significantly different between 
the groups. ENL treatment of E0771 cells in vitro (without LPS) significantly increased ERb 
expression and decreased NF-kB activation.  
 
Conclusions: SDG supplementation reduced mammary tumor growth in association with an 
increase in ERb expression and a decrease in local, but not systemic, inflammatory signaling. 
Given that ERb activity has been linked to reduced NF-kB activation in other cancer types, the 
mechanistic links between SDG, ERb expression, NF-kB activity, and mammary tumor growth 
will be further investigated. 
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Introduction 
Breast Cancer Prevalence and Mortality 
Breast cancer is the most common form of cancer seen in females. In 2013, an estimated 
3,053,450 women had breast cancer in the United States and according to 2011-2013 data from 
the National Cancer Institute (NCI), 12.4% of women will develop breast cancer over their 
lifetime. It is also the fourth leading cause of cancer death in the United States. Data from the 
NCI shows that the number of deaths from breast cancer was 21.5 per 100,000 women per year 
from 2009 to 2013. The rate of new case diagnosis has steadily increased over the last 40 years, 
but this is primarily due to improved and increasingly widespread mammography screening, 
which has increased early treatment and thereby improved prognosis. This has caused the death 
rate from breast cancer to steadily fall, including an average decrease of 1.9% each year from 
2004 to 2013.1 
Breast cancer is most common among women who are middle-aged or older as less than 
5 percent of breast cancer occurs in women less than 40 years of age. Young women diagnosed 
with breast cancer typically have a genetic predisposition, usually a BRCA1 or BRCA2 gene 
mutation2. However, although younger women have a lower risk of diagnosis, they also tend to 
have more aggressive tumors and lower survival rates3. This is one reason breast cancer is the 
leading cause of death for women between the ages of 20 and 392. 
Breast cancer can be subdivided into several subtypes, and some women are more likely 
to develop certain subtypes. The two broad groups include estrogen-receptor (ER)-positive and 
ER-negative tumors4. ER positive breast cancer can be further divided into luminal A, which is 
the least aggressive and most common subtype among postmenopausal women, luminal B, and 
	 6 
normal-like tumors4,5. Luminal A and normal-like tumors express estrogen receptor alpha (ERa) 
and the progesterone receptor (PR), both of which can be targets for treatment5. 
Consequently, patients with tumors lacking expression of either ERa or PR have a 1.5 to 2-fold 
higher risk of mortality6. Therefore, luminal B tumors, which have ERa but lack PR, are more 
aggressive than luminal A5. The other breast cancer subtypes, which include HER-2 positive, 
basal-like, and claudin-low tumors, are typically ERa negative, making them more aggressive4. 
The current study utilized a mouse mammary tumor cell line that clusters with the 
molecular signature of human basal-like tumors, but expresses ERa. Basal-like tumors are 
similar to basal epithelial cells and are typically highly aggressive, leading to very poor 
prognosis. This aggressiveness is partially a result of the basal-like gene products which suppress 
cell death by apoptosis and increase cellular proliferation, invasion and migration.4 
Inflammation and Cancer 
It is now clear that cell proliferation alone does not cause cancer, but rather it takes 
sustained cell proliferation and an environment rich in growth factors, DNA-damage-promoting 
agents such as reactive oxygen species (ROS), and inflammatory cells to effectively increase 
cancer risk7. An inflammatory response typically follows damage to cells and tissues by factors 
such as bacteria, toxins, heat, and trauma8. A multifaceted network of chemical signals, including 
histamines, prostaglandins, chemokines, pro-inflammatory cytokines and others, begin the 
activation and migration of leukocytes, including neutrophils, monocytes, and eosinophils, 
through the blood vessels into the damaged tissue to destroy the dead or severely injured cells8,9. 
Neutrophils are typically the first to arrive on site, followed by the monocytes. Monocytes 
differentiate into macrophages, which are the major source of growth factors and cytokines that 
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enhance the inflammatory response by dilating blood vessels, controlling immune cell 
populations, and mediating many other aspects of the inflammatory response9. 
Studies have found that this inflammatory response plays a significant part in cancer 
development and progression. The progression usually starts with exposure to carcinogens that 
alter DNA10,11. These alterations may go undetected until a second signal is received. This signal 
comes from exposure to factors such as those released from damaged tissue, as well as hormones 
and chronic inflammation, among others9. The signal then leads to increased cell proliferation, 
and recruitment of inflammatory cells which, during a typical inflammatory response would 
eradicate the damaged and/or dead cells and cause increased cell proliferation for the 
reestablishment of tissue homeostasis9,12. However, in cancer, these chemical signals persist over 
time which may increase risk of tumor development and support its progression12. For example, 
these signals increase production of ROS, which promote DNA damage and decrease DNA 
repair. The result is increased proliferation of cells that have lost control over normal growth 
patterns and that proliferation continues since there are no anti-inflammatory signals to resolve 
the response9. 
Over the past several years, the association between inflammation and breast cancer has 
been thoroughly explored. One of the most persuasive pieces of evidence came in 2009 with a 
multisite study of 734 women who were successfully treated for early stage breast cancer and 
then presented high levels of circulating acute phase proteins (APPs) almost three years after 
treatment. These high levels of APPs, which are commonly associated with inflammation, were 
then associated with a two-fold increase in risk of the recurrence of the cancer and mortality13. 
These results matched with previous studies indicating an inflammation-breast cancer link and a 
large number of studies have been conducted linking specific inflammatory chemokines and 
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cytokines with increased breast cancer risk13,14. Some of these include C-reactive protein (CRP), 
TNF-a9, IL-1b15, CCL2, and CCL514, among many others. 
Transcription Factor NF-kB, Inflammation, and Cancer 
NF-kB is a transcription factor that is activated by stimuli such as growth factors, pro-
inflammatory cytokines, chemokines, other inflammatory molecules, chemotherapeutic drugs, 
and psychological stress, among others. Its activation increases expression of genes associated 
with resistance to apoptotic signals, cell proliferation and survival, angiogenesis, metastasis, 
tissue invasion, and inflammation16,17. These genes include those that code for pro-inflammatory 
cytokines, chemokines, adhesion molecules, and APPs16. Several cancers have been shown to 
have increased NF-kB activation including pancreatic cancer17, bladder cancer18, breast cancer19 
colon cancer20, prostate cancer21, and several others. Therefore, inhibition of this pathway seems 
favorable in reducing inflammation and its pro-tumor effects. In fact, several studies have found 
that inhibiting NF-kB can restrict tumor growth17,22. The inhibition agents studied have included 
parthenolide16 and a calorie restricted diet17, among others, and it has been suggested that 
phytoestrogens may also inhibit activation of the NF-kB pathway18. 
Secoisolariciresinol diglycoside (SDG) and Breast Cancer 
Secoisolariciresinol diglycoside (SDG) is a polyphenolic plant lignan, which is a major 
class of phytoestrogens, found in flax and sesame seeds, legumes, whole grains, fruits and 
vegetables. It is further metabolized in the gut into bioactive enterolignans: enterolactone (ENL) 
and enterodiol (END). Both ENL and END may modulate signaling of ERa and ERb, which 
function as transcription factors for genes that affect the growth, proliferation, and differentiation 
of cells23,24. ERa activation is associated with promotion of breast cancer cell proliferation, 
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survival, and motility23,25 while ERb activation is associated with decreased cell growth, motility, 
and invasion26,27,28. 
To date, eleven population studies have examined the association between ENL/END 
exposure and breast cancer risk. They largely found, through serum ENL, urinary ENL 
excretion, and estimated SDG intake measurements, that there may be an inverse relationship 
between the two variables. However, these results may be limited to ERa- tumors. One meta-
analysis found that high lignan exposure may be associated with decreased breast cancer risk 
while others also found strong evidence that higher serum ENL levels were inversely associated 
with breast cancer risk29,30. Furthermore, five studies have examined the association between 
ENL/END exposure and breast cancer outcome. All studies found associations between higher 
serum ENL or estimated SDG intake and lower breast cancer mortality31,32,33. However, these 
studies were largely conducted with postmenopausal women, leaving considerable debate 
regarding the portion of the population most likely to benefit from SDG supplementation. 
Pre-clinical studies have found that ENL and END decrease tumor proliferation, 
adhesion, migration, invasion and angiogenesis while it increases apoptosis34,35,15,36. Specifically, 
Chen et al34 found that ENL and END reduce breast cancer cell adhesion, invasion and migration 
in vitro. Lindahl et al15 found that tumors treated with tamoxifen and then fed a diet rich in ENL 
showed a decrease in production of IL-1b, a proinflammatory cytokine that promotes tumor 
angiogenesis. Furthermore, in vivo studies done by Saarinen et al37,38 found that ENL inhibits 
mammary tumor growth. 
These pre-clinical studies, among others demonstrating strong evidence of the anti-tumor 
effects of ENL/END, led to a clinical study further testing SDG’s effects. This pilot clinical 
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study, conducted by Fabian et al, included 45 pre-menopausal women with a high risk of breast 
cancer. After taking 50 mg/d of SDG for 12 months, a decrease in the proliferation marker Ki67 
expression and atypical cytology in the subjects’ random periareolar fine needle aspirate 
(RPFNA) samples was seen39. In an ongoing full clinical trial, Fabian and colleagues have also 
seen an increase in ERb expression in RPFNA samples from subjects receiving SDG (personal 
communication). These findings suggest that SDG’s anti-tumor effects may be mediated in part 
by enhancing ERb signaling. 
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Goal and Hypotheses 
The primary goal of the current study was to determine whether SDG suppresses 
mammary tumor growth via inhibition of inflammatory signaling in the normal mammary and 
tumor tissue. This was accomplished through two specific aims. One was to determine the 
impact of SDG on tumor proliferation, apoptosis and inflammatory markers in the E0771 
transplant model via immunohistochemistry (IHC) detection of Ki67, cleaved caspase-3, 
phospho-p65 and p-STAT3 in the tumor; quantification of macrophage infiltration in the normal 
mammary and tumor tissue via IHC and qPCR detection of F4/80; and measurement of serum 
cytokine levels via multiplex immunoassay. We hypothesized that SDG supplementation will 
decrease tumor proliferation and increase apoptosis. Furthermore, since we previously found in a 
separate pilot study that SDG supplementation decreases mammary gland expression of several 
pro-inflammatory genes, we hypothesized that SDG will decrease macrophage infiltration into 
the mammary gland and tumor. Finally, we hypothesized that there will be a decrease in the 
concentration of pro-inflammatory cytokines with SDG supplementation. 
The second specific aim was to define the role of ENL’s anti-inflammatory activity in 
SDG’s anti-tumor effects by examining the effects of ENL on inflammation through NF-kB 
modulation and the expression of NF-kB target genes in the tumor. Our hypothesis is that NF-kB 
activation will be reduced and subsequent target genes will be down-regulated upon SDG 
supplementation. 
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Methods 
Animal Study: Female, twelve-week-old C57BL/6 mice (n=40) were randomized to either a 
control diet (10% kcal from fat, n=20) or a control plus SDG diet (100 mg/kg food, n=20) after 
two weeks of acclimation on the control diet. After eight weeks on the randomly assigned diet, 
serum was collected by submandibular bleed and the mice were orthotopically injected with 
E0771 mammary tumor cells in the fourth mammary gland. Approximately 3 weeks after being 
injected with E0771 cells, the mice were sacrificed by carbon dioxide euthanasia and cervical 
dislocation, after which, serum, distal mammary fat pad (DMFP), adjacent mammary fat pad, 
tumor tissue, lungs, liver, colon, and stool were collected.  
Body Weight and Fat Composition Analysis: 
Body weight was recorded at baseline and then every week until the end of study. Body 
fat composition was measured by Dual-energy X-ray absorptiometry (DEXA). 
 Tumor Weight and Volume Analysis: 
 Mammary tumors were weighed after removal during necropsy. Mammary tumor 
dimensions were also measured with digital calipers during necropsy. The ellipsoid equation was 
used to determine volume: 1/6p(D1 x D2 x D3).  
Serum Analysis:  
 Blood was collected in 1.5 mL microcentrifuge tubes during necropsy, allowed to clot for 
30 minutes at room temperature, and centrifuged at 10,000 g for 10 minutes. The serum was then 
collected into cyrovials and stored at -80° C. Serum cytokines were then analyzed by Bio-Plex 
Mulitiplex Immunoassay on a Bio-Plexâ Magpix Multiplex Reader (Bio-Rad) by following the 
manufacturer’s protocol.    
 DMFP Analysis: 
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 DMFP was analyzed by qPCR using Taqmanä Gene Expression Assays (Applied 
Biosystems) to determine relative mRNA levels of ERa and ERb. DMFP inflammation was 
measured by Qiagen’s Mouse Cancer Inflammation and Immunity Crosstalk RT2 Profiler PCR 
Array and quantitative RT-PCR for F4/80 and CRP gene expression using Taqmanä Gene 
Expression Assays, all of which were read on a ViiAä7 RT-PCR System (Applied Biosystems). 
DMFP tissue was also stained by immunohistochemistry (IHC) for F4/80 protein expression.  
Tumor Analysis: 
 Tumors were analyzed by qPCR using Taqmanä Gene Expression Assays (Applied 
Biosystems) to determine the relative mRNA levels of both ERa and ERb. Tumors were also 
stained by IHC for p-p65 (Ser536) and p-STAT3 (Tyr705) protein expression. Inflammation was 
measured by Qiagen’s Mouse NF-kB Signaling Target RT2 Profiler PCR Array, read on a 
ViiAä7 RT-PCR System (Applied Biosystems).  Proliferation of tumors was determined by 
staining for Ki67 expression via IHC while apoptosis of tumor cells was determined by staining 
for cleaved caspase-3 expression via IHC. 
 
ERa and ERb Expression in E0771 cells: Mouse E0771 mammary tumor cells were seeded in 
6-well plates for qPCR with four time points (1 hr, 6 hrs, 24 hrs, and 48 hrs) and two 
concentrations each of ENL and END (ENL: 1 µM and 150 nM; END: 1 µM and 100 nM).  
ENL and END were added to complete media. The treatments were: vehicle (ETOH), ENL (150 
nM and 1 µM), END (100 nM and 1 µM), ENL+END (150 nM + 100 nM and 1 µM + 1 µM). 
After the specified amount of time, the media was suctioned off, the cells were harvested with 
Trizol reagent (Sigma-Aldrich) into 1.5-mL microcentrifuge tubes to be stored at -80° C. RNA 
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isolation and subsequent cDNA synthesis was conducted and ERa and ERb expression was 
measured by qPCR using Taqmanä Gene Expression Assays. 
 
NF-kB ELISA: Mouse E0771 mammary tumor cells were seeded in 6-well plates for a NF-kB 
ELISA with three time points (1 hr, 8 hr, and 24 hrs) and two concentrations of ENL (1 µM or 
10 µM) with or without lipopolysaccharide (LPS, 10 ng/ml). ENL and LPS were added to 
complete media. The treatments were: vehicle (ETOH), 1 µM ENL, and 10 µM ENL +/- LPS. 
After the specified amount of time, the media was suctioned off, the cells were placed on ice and 
washed with ice-cold PBS + phosphatase inhibitor (2 mL/well), and the cells were then harvested 
in PBS + phosphatase inhibitor (0.5 mL/well) into 1.5-mL microcentrifuge tubes. The cells were 
centrifuged at 4,000 rpm for 5 minutes, the supernatant removed and the cell pellets stored at -
80°C. Active Motif’s Nuclear Extract Kit was used to isolate the nuclear fraction of the cells. 
Active Motif’s TransAMÒ NF-kB p65 ELISA was then used to measure p65 in the nuclear 
fractions by following the manufacture’s protocol. 
      
Statistical Analysis: All data was analyzed using GraphPad Prism 6 software. Differences 
between the experimental groups in the animal study were analyzed by Student’s t-test and 
differences between conditions in the in vitro experiments were analyzed by one-way ANOVA 
using Tukey’s multiple comparisons test. P < 0.05 was considered statistically significant. 
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Results 
Animal Study Results: 
Body Weight and Percent Body Fat Analysis: 
 The SDG and Control groups never differed significantly in body weight throughout 
study duration (Figure 1A). Percent body fat at study endpoint also did not differ significantly 
between groups (p=0.91; Figure 1B).  
 
 
 
 
 
 
Figure 1. (A) Body weight over time. (B) Percent body fat.  
Tumor Weight and Volume Analysis: 
 Tumor volume was significantly smaller in the SDG group in comparison to the Control 
group (p=0.019; Figure 2A). Furthermore, tumor weight was lower in the SDG group compared 
to the Control group but this difference was not statistically significant (p=0.064; Figure 2B). 
   
Figure 2. (A) Tumor volume (B) Tumor weight. *p<0.05.   
*	
A	 B	
A	 B	
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Serum Cytokines Analysis: 
Serum concentrations of cytokines IL-1b, IL-10, IL-17A, GM-CSF, IFN-g, IL-6, MCP-1, 
and TNF-a were not significantly affected by SDG supplementation (Figure 3).   
  
Figure 3. Serum cytokine concentrations.  
DMFP Analysis: 
 There was no significant difference between the SDG and Control groups in DMFP ERa 
expression (p=0.32; Figure 4A); however, ERb expression was significantly higher in the SDG 
group versus the Control group (p=0.0011; Figure 4B).  
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Figure 4. (A) DMFP ERa expression. (B) DMFP ERb expression. **p<0.001.  
 
 Furthermore, there was a significant decrease in the expression of both F4/80 (p=0.024; 
Figure 5A), a macrophage marker, and CRP (p=0.011; Figure 5B), an inflammatory marker, in 
the DMFP with SDG supplementation, as measured by qPCR. SDG supplementation also 
downregulated the expression of 20 inflammatory signaling genes by more than 2-fold, and 
many of these downregulated genes are NF-kB target genes (Figure 5C, Table 1). However, IHC 
staining of DMFP for F4/80 indicated no significant difference between groups (p=0.24; Figure 
6).  
 
     
 
 
 
 
 
 
A	 B	
A	 B	
		* 
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Figure 5. (A) DMFP F4/80 Expression. (B) DMFP CRP Expression. (C) Inflammatory signaling 
genes downregulated with SDG supplementation (seen in green). *p<0.05.  
 
 
Gene Fold Regulation Description 
Ccr4 -3.73 The protein encoded by this gene has been found to promote tumor growth and lung 
metastasis in breast cancer40. 
Cxcr5 -3.66 A higher expression of this gene in breast cancer cells is associated with invasive 
breast cancer41.  
Ctla4 -3.61 It’s expression in tumor cells is associated with worse prognosis42.  
Ccl2 -2.58 Codes for a protein that recruits monocytes, memory T cells, and dendritic cells to 
site of inflammation43,44. It has also been found to promote metastasis45.  
Ccl5 -3.15 Expression is associated with breast cancer progression and it has been found to 
promote proliferation and invasion46,47.  
Ccl20 -2.93 Induces migration and proliferation of breast cancer cells and attracts tumor-
promoting immunosuppressive cells to the tumor microenvironment48,49.  
Table 1. Inflammatory Genes Under-Expressed in the DMFP Upon SDG Supplementation.  
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Figure 6. (A) DMFP F4/80 expression determined by IHC staining. (B) Representative images 
of F4/80 IHC staining in DMFP. 
 
Tumor Analysis: 
 There was an increase in ERa expression in the SDG group compared to Control, but this 
difference was not significant (p=0.058; Figure 7A). ERb expression was significantly increased 
in the SDG group in comparison to the Control group (p=0.032; Figure 7B).  
 
 
 
 
 
 
 
 
 
Figure 7. (A) Tumor ERa Expression. (B) Tumor ERb Expression. *p<0.05. 
 
 IHC staining analysis indicated a significant increase in p-p65 expression, an indicator of 
NFkB activity, in the SDG group compared to the Control group (p=0.0068; Figure 8A and 8B). 
However, no significant difference was found in p-STAT3 expression, a pro-inflammatory 
signaling pathway activation marker, between groups (p=0.72; Figure 8C and 8D). Furthermore, 
SDG supplementation did not significantly affect tumor proliferation as measured by Ki67 
A	 B	
F4/80	Expression	
Control	 SDG	
A	 B	
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expression (p=0.42; Figure 9A and 9B) nor apoptosis as measured by cleaved caspase-3 
expression (p=0.69; Figure 9C and 9D). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. (A) p-p65 Expression. (B) IHC Snapshots of p-p65 Expression. (C) p-STAT3 
Expression. (D) IHC Snapshots of p-STAT3 Expression. **p<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A	 B	
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Control	 SDG	
C	 p-STAT3	Expression	
Control	 SDG	
D	
A	
Ki67	Expression	
Control	 SDG	
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Figure 9. (A) Ki67 expression. (B) IHC snapshots of Ki67 expression. (C) Cleaved caspase-3 
expression. (D) IHC snapshots of cleaved caspase-3 expression.  
 
 The NF-kB array indicated that 43 NF-kB target genes were significantly 
downregulated with SDG supplementation (Figure 10). Many of these genes encode proteins 
with pro-tumor functions (Table 2). However, some of the genes downregulated, including IL-15 
and Stat1, have anti-tumor effects.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. NF-kB target genes downregulated upon SDG supplementation (seen in green).  
 
 
 
 
C	
Control	 SDG	
Cleaved	caspase-3	Expression	
D	
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Gene Fold Regulation P value Description 
C3 -4.34 0.0077 Aids activation of the complement system, which may increase growth 
of tumors through immunosuppression50. 
Ccl12 -3.72 0.012 An ortholog of Ccl2, which recruits monocytes to increase breast cancer 
metastasis51. 
Ccr5 -4.55 0.00017 This chemokine receptor may influence human breast cancer 
progression by regulating p53 transcriptional activity52.  
Cd74 -3.02 0.021 Overexpression is linked to increased metastasis and invasion within 
breast cancer tumors53.  
Cxcl10 -2.27 0.043 Associated with chronic inflammation, tumor development, and 
metastasis, among other human diseases. It is also a major marker of 
disease severity.54 
Fasl -5.45 0.00051 If overexpressed, it can allow a tumor to escape the immune response 
by inducing apoptosis of immune cells55.  
Il1b -2.42 0.049 Promotes tumor development and angiogenesis through regulation of 
the inflammatory response15.  
Mmp9 -2.97 0.0025 It’s role in extracellular matrix remodeling aids tumor invasion, 
metastasis, angiogenesis, and growth56. 
Nfkb2 -2.22 0.0057 Codes for p100 protein whose inhibition may suppress cancer stem cell 
activity in some breast cancer tumors57.  
Nqo1 -2.05 0.0031 Usually overexpressed in breast cancer cells and may be a good target 
for treatment58. 
Tnf -2.56 0.0028 Codes for the inflammatory cytokine TNFa, which is secreted by 
inflammatory cells and involved in all aspects of carcinogenesis 
including cell survival, proliferation, invasion, angiogenesis, and 
metastasis, among others59.   
Vcam1 -4.87 0.0083 Normally mediates leukocyte movement to inflamed tissues; however, 
overexpression can allow tumor cells to escape the immune system60.  
Xiap -2.54 0.014 Codes for a protein that inhibits apoptosis by inhibiting caspase-3 and 
caspase-761. 
B2m -2.28 0.0085 Codes for a component of the MHC class I complex and allows tumor 
cells to escape the immune response62. 
Table 2. NF-kB Target Genes Significantly Downregulated Upon SDG Supplementation. 
 
 
ERa and ERb Expression in E0771 Cells Analysis:  
 A significant increase in E0771 cell ERb expression was seen following a 48-hour 
treatment with 1 µM ENL (p=0.0184; Figure 11). No significant differences were noted at other 
time points (data not shown).  
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Figure 11. ERb Expression in Vehicle vs. 1 µM ENL treatments at 48-hours. *p<0.05. 
NF-kB ELISA:  
 Nuclear localization of the p65 subunit of NF-kB was significantly downregulated after 
an 8-hour treatment with ENL at the 1 µM and 10 µM doses (without LPS) in comparison to 
vehicle (p=0.0051 and p=0.0019, respectively; Figure 12). No significant differences were noted 
at other time points (data not shown).  
   
 
 
 
 
 
 
 
 
 
Figure 12. Relative p65 activation for the 8-hour time point without LPS. Different letters 
indicate significant differences, p<0.05.   
 
 
 
 
 
 
 
 
 
a	
b	
b	
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Discussion 
This study aimed to explore whether SDG has anti-tumor effects in a mouse model of 
pre-menopausal ERa+ breast cancer and if these effects are mediated by SDG’s anti-
inflammatory activity.  
The study produced substantial evidence indicating that inflammatory signaling 
decreased upon SDG supplementation. This effect appears to be limited to local inflammation, as 
there was no difference between groups in serum cytokine levels, but there was a significant 
decrease in the expression of F4/80 (a marker of macrophage infiltration), CRP (a marker of 
inflammatory signaling), and more than 20 inflammatory signaling genes in the DMFP. 
Furthermore, there was a significant decrease in p-p65 expression (a marker of NF-kB activity) 
in the tumor, as well as in tumor expression of more than 40 NF-kB target genes.  
It was also observed that many of the downregulated NF-kB target genes normally aid in 
inflammation mediation in some capacity. For example, Il1b codes for IL-1b which is a potent 
pro-inflammatory cytokine that promotes tumor development and angiogenesis through 
mediation of the inflammatory response15,63. Furthermore, this observed decreased in Il1b 
expression following SDG supplementation mirrors the results of a study by Lindahl et al15 
which also saw a decreased in vivo release of IL-1b following ENL treatment in a mouse model. 
Another observed downregulated gene was Tnf, which codes for the pro-inflammatory cytokine 
TNFa. TNFa is involved in all parts of carcinogenesis including cell proliferation, invasion, 
angiogenesis and metastasis. It can also induce NF-kB activation59. Furthermore, a study by 
Datta et al64 found that the inflammatory cytokine CXCL10, which is encoded by Cxcl10, tends 
to be overexpressed in breast cancer cells and promote tumor growth. CXCL10 has been 
associated with chronic inflammation, immune dysfunction, and other human diseases, and it is 
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considered a major biological marker mediating disease severity54. Finally, Ccl12 codes for 
CCL12, an ortholog of CCL2, which has been shown to recruit inflammatory monocytes to aid 
in breast tumor metastasis51. 
Many of the downregulated NF-kB target genes were associated with other pro-tumor 
actions. For example, Vcam1, Bcm, and Fasl genes all code for proteins that allow the tumor to 
escape the effects of the immune system60,62,55. In addition, several downregulated genes encode 
proteins that increase metastasis and tumor invasion, such as Cd74, or inhibit apoptosis, such as 
Xiap53,61. 
However, it was also observed that some of the downregulated genes have anti-tumor 
functions. For example, Stat1 encodes STAT1, which is considered a tumor suppressor since it 
induces anti-proliferative and pro-apoptotic responses within tumor cells65. Another example is 
Il15, which encodes IL-15, a cytokine that activates natural killer cells and suppresses cancer cell 
growth66. Given that both pro-tumor and anti-tumor genes were downregulated in the SDG 
group’s tumors, we cannot conclude that NF-kB inhibition mediates SDG’s anti-tumor effects 
without further mechanistic investigation.    
We also observed that SDG caused a significant increase in ERb expression in the DMFP 
and tumor tissue in our animal study while ENL treatment increased E0771 cell ERb expression 
in our cell culture experiments. These results were similar to those from the on-going clinical 
trial conducted by Carol Fabian and colleagues which indicate that SDG supplementation 
promotes an increase in ERb expression in RPFNAs.  
These results are intriguing since several studies, including those by Kontos et al18 and 
Mak et al21 in urinary bladder carcinogenesis and prostate cancer, respectively, strongly suggest 
that increased ERb signaling can inhibit NF-kB activity. The current study results suggest this 
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may also be true for breast cancer, as a significant increase in tumor ERb expression was 
accompanied by a significant decrease in p-p65 expression and a decrease in 43 NF-kB target 
genes in the SDG group. Furthermore, the observation that ENL increases E0771 cell ERb 
expression in cell culture combined with the significant decrease in E0771 nuclear p65 
localization upon ENL treatment also supports this relationship. However, more studies will need 
to be conducted to determine whether SDG-induced ERb expression is causally linked to 
reduced NFkB activity and inhibition of mammary tumor growth. 
Although SDG supplementation significantly reduced tumor volume, we found no 
significant differences in tumor proliferation or apoptosis. Tumor Ki67 expression failed to 
mirror the results of the pilot clinical trial conducted by Fabian et al37, which demonstrated a 
decrease in this proliferation marker in RPFNA samples following SDG supplementation. 
Furthermore, cleaved caspase 3 staining indicated that there was no increase in tumor apoptosis. 
These results may be due to errors in IHC staining and both proliferation and apoptosis levels in 
the tumors will be examined further via alternative markers.  
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Conclusion 
We conclude that SDG supplementation reduces E0771 mammary tumor growth and this 
may be related to SDG’s stimulation of ERb expression and inhibition of local (but not systemic) 
inflammatory signaling. 
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